Skip to content
Latest
HealthGlobal News

FDA to require vision loss warning on GLP-1 drug labels

By Rachel Goodman

The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.

Read Original Article

More in Health

From the blog